




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07K 5/037, 5/093, 5/113, 5/02	A1	(11) International Publication Number: WO 97/25342 (43) International Publication Date: 17 July 1997 (17.07.97)
(21) International Application Number: PCT/US96/20042 (22) International Filing Date: 20 December 1996 (20.12.96) (30) Priority Data: 08/582,966 4 January 1996 (04.01.96) US (71) Applicant: TERRAPIN TECHNOLOGIES, INC. [US/US]; 750-H Gateway Boulevard, South San Francisco, CA 94080 (US). (72) Inventors: LYTTLE, Matthew, H.; P.O. Box 1166, Point Reyes Station, CA 94956 (US). KAUVAR, Lawrence, M.; 1205 Cole Street, San Francisco, CA 94117 (US). (74) Agents: MURASHIGE, Kate, H. et al.; Morrison & Foerster L.L.P., 2000 Pennsylvania Avenue, N.W., Washington, DC 20006-1888 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: TETHERED PRODRUGS BY VIRTUE OF COVALENT LINKAGE WITH ANALOGS OF GLUTATHIONE**(57) Abstract**

Compounds of formula (1) and the amides, esters, mixed ester/amides and salts thereof are useful as tethered prodrugs that slow the rate of clearance of an active biomolecule through the MRP pump. In the compounds of formula (1), S* is S-O, O-S-O, S-NH, HN-S=O, Se=O, O-Se-O, Se-NH, HN-Se=O, S*R' wherein R' is alkyl (1-6C), or S* is -O-C=O or -HN-C=O; YCO is selected from the group consisting of γ -Gly, β -Asp, Glu, Asp, γ -GluGly, β -AspGly, GluGly and AspGly; AA_C is an amino acid linked through a peptide bond to the remainder of said compound of formula (1); each R is independently H or a noninterfering substituent; (conj) is a conjugated system; m is 0 or 1; each of the dotted lines represents a covalent bond between the biomolecule and C*, C⁺, or a carbon in the conjugated system if present with the proviso that one and only one said bond is present; and "biomolecule" represents a moiety which becomes biologically active when covalent bond (a) is cleaved to donate an electron pair to biomolecule.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam


TETHERED PRODRUGS BY VIRTUE OF COVALENT LINKAGE WITH ANALOGS OF GLUTATHIONE.

Technical Field

The invention relates to drug delivery systems, in particular, prodrugs that depend on glutathione S-transferase (GST) for activation. In particular, the invention concerns prodrugs wherein the active form of the drug resists clearance through the multidrug resistance associated protein (MRP) system by virtue of retained association with an analog form of glutathione.

Background Art

PCT application WO 95/09866 published 13 April 1995 and incorporated herein by reference, discloses a group of GST-activated compounds which rely on interaction of a prodrug form of a drug or toxin with glutathione S-transferase and the resulting abstraction of a proton by the enzyme, releasing an electron pair which mediates, in turn, the release of the drug or toxin. These compounds are generally of the following formula, where the pathway of released electrons from hydrogen ion abstraction is indicated.



In these compounds,

L is an electron withdrawing leaving group;
 S^x is an oxidized form of S, Se or C, e.g.,
 $\text{S}=\text{O}$, $\text{O}=\text{S}=\text{O}$, $\text{S}=\text{NH}$, $\text{HN}=\text{S}=\text{O}$, $\text{Se}=\text{O}$, $\text{O}=\text{Se}=\text{O}$, $\text{Se}=\text{NH}$, $\text{HN}=\text{Se}=\text{O}$,
 $\text{S}^+\text{R}'$ wherein R' is alkyl (1-6C) or $\text{O}-\text{C}=\text{O}$ or $\text{HN}-\text{C}=\text{O}$;
 each R is independently H or a noninterfering substituent;

SUBSTITUTE SHEET (RULE 26)

- 2 -

n is 0, 1 or 2,

YCO is selected from the group consisting of γ -Glu, β -Asp, Glu, Asp, γ -GluGly, β -AspGly, GluGly and AspGly; and

5 AA_C is an amino acid linked through a peptide bond to the remainder of the compound.

As explained in the above-cited PCT application, specificity with respect to particular tissues or targets can be manipulated, mainly through
10 appropriate choices for AA_C, and to a lesser extent, YCO.

The reason for this is that the nature of the glutathione analog portion of the prodrug determines which of the many isozymes of GST are effective in releasing the biologically active moiety. The nature of
15 the leaving group will determine the biological effect of administering the prodrug. Included among the leaving groups described are nitrogen mustards and other cytotoxic substances, as well as various antibiotics, indicator molecules, and other groups.

20 Although the prodrugs described in the PCT application are effective, they may also be cleared more quickly than desired from the target cells or tissue by virtue of elevated levels of multidrug resistance associated protein (MRP) which transports GSH-conjugated
25 substances out of the cell as described by Jedlitschky, G. et al., *Cancer Research* (1994) 54:4833. For example, in the case of the phosphoramidate mustards, displacement of a chloride ion from one of the 2-chloroethyl groups by the sulfhydryl group of glutathione results in a GSH-
30 conjugate which can then be cleared by the MRP system.

It would be desirable to provide prodrugs which not only release active forms of the drugs per se, but also result in a lowered rate of clearance of the activated drug. The present invention provides two
35 approaches to this problem. One approach resides in selecting, as the glutathione analog in the prodrug, a glutathione analog that itself interacts with the MRP,

SUBSTITUTE SHEET (RULE 26)

e.g., in competition with GSH. Thus, after the prodrug is cleaved by GST, the glutathione analog can inhibit the transport of other moieties, such as the activated drug or toxin. This approach is workable, however, only where
5 the specificity desired for the prodrug release permits this choice to be made.

In a more universal approach, the prodrug is designed to activate, but not to release completely the biologically active moiety associated with it; the
10 biologically active moiety remains tethered to the glutathione analog, reducing its susceptibility to GST-mediated conjugation to free GSH. Thus, it has reduced ability to form a compound which is effectively cleared by the MRP system.

15

Disclosure of the Invention


The invention provides an improvement in the design of certain prodrugs, permitting lower dosages by virtue of inhibiting the rate of clearance of the
20 activated drug. The prodrugs are designed so as to interfere with the clearance of the activated drug through the MRP efflux system.

Thus, in one aspect, the invention is directed to a method to enhance the effectiveness of prodrug
25 administration, which method comprises assessing a panel of candidate glutathione analogs for their ability to interact with the MRP system;

selecting from said panel an analog which interacts with said MRP system;

30 synthesizing a prodrug which is a conjugate of the appropriate form of the selected analog with a substance of the desired biological activity; and administering the resulting prodrug to a subject in need of treatment with the biologically active
35 compound.

In another aspect, the invention is directed to compounds of the formula:



wherein S^x is $\text{S}=\text{O}$, $\text{O}=\text{S}=\text{O}$, $\text{S}=\text{NH}$, $\text{HN}=\text{S}=\text{O}$, $\text{Se}=\text{O}$,
 15 $\text{O}=\text{Se}=\text{O}$, $\text{Se}=\text{NH}$, $\text{HN}=\text{Se}=\text{O}$, $\text{S}^+\text{R}'$ wherein R' is alkyl (1-6C),
 or S^x is $-\text{O}-\text{C}=\text{O}$ or $-\text{HN}-\text{C}=\text{O}$;

YCO is selected from the group consisting of
 γ -Glu, β -Asp, Glu, Asp, γ -GluGly, β -AspGly, GluGly and
 AspGly; and

20 AA_c is an amino acid linked through a peptide
 bond to the remainder of said compound of formula (1);

(conj) is a conjugated system permitting
 transfer of electron pairs, such as $-\text{CR}=\text{CR}-$; $-(\text{CR}=\text{CR})_2-$
 or -phenylene-;

25 m is 0 or 1; each R is independently H or non-
 interfering substituent;

the dotted lines represent alternative covalent
 bonds tethering the biomolecule to the indicated C ; and

"biomolecule" represents a moiety which is
 30 biologically active when covalent bond (a) is severed.


Thus, one and only one covalent bond will be
 present among the group consisting of the dotted line
 linking biomolecule to C^+ , the dotted line linking
 biomolecule to C^+ and the dotted line linking the
 35 biomolecule to a carbon in the conjugated system, if
 present.

Thus, in the compounds of formula (1), when the
 hydrogen ion α to S^x is abstracted, releasing electrons
 (through the conjugated system, if present) ultimately to
 40 sever covalent bond (a), the "biomolecule" or portion
 thereof becomes biologically active, although it remains

tethered to the remainder of the molecule either by covalent linkage to C* or by covalent linkage to C⁺ or by covalent linkage to a carbon in the conjugated system if present. The nature of the coupling through covalent

5 bond (a) of the biomolecule to the remainder of the compound of formula (1), i.e., the atom of the biomolecule that participates in the covalent bond is dependent on the nature of the biomolecule.

In one embodiment, the biomolecule contains a
10 phosphoramidate mustard. In this embodiment, preferred are compounds of the formula



wherein S^x, YCO, AA_C, (conj), m, and R are
15 defined as above;


n is an integer of 0-4;

each X is independently O, NH or S;

Z is a moiety which, when associated with
P(O)X¹X² is biologically active; and

20 the dotted lines represent alternative covalent bonds linking CR₂ and thus X² to the remainder of the molecule -- i.e., to C*, C⁺, or a carbon in the conjugated system if present.

In another set of preferred embodiments, the
25 compounds of the invention are of the formula



15 wherein S^x, YCO, AA_C, (conj), m, and R are defined as above, and "drug residue" represents a moiety which, when inclusive of the N(H) shown adjacent to it, is a biologically active drug. (In some drugs including those represented as illustrations herein, the N is in a
20 2° amino form, for example as a member of a heterocyclic ring, and thus no H should be shown. For illustration, the formulas herein display N(H) since H would be present if N is a 1° amino in the drug.) As in the formulas set forth above, the dotted lines represent alternative
25 tethering covalent bonds to link the drug residue to the remainder of the molecule, either to the C*, C⁺, or a carbon of the conjugated system if present. Again, the location of the tethering covalent bond in the drug residue is determined by the nature of the drug residue.
30 When the covalent bond (a) is severed, the (drug residue)-NH₂ or (drug residue)-NH in the case of secondary amines, becomes biologically active and remains tethered to the remainder of the molecule through one and only one of the dotted alternative covalent bonds shown.

35 In all of the above formulas (R) indicates that R will be present when the dotted line covalent bond is absent and absent when the covalent bond represented by the dotted line is present.

In other aspects, the invention is directed to
40 pharmaceutical compositions containing the compounds of
formula (1) and to methods of modulating the metabolism

of target cells by administering the compounds of formula (1) or pharmaceutical compositions thereof.

Brief Description of the Drawings

5 Figure 1 shows a reaction scheme for the synthesis of some of the embodiments of the general formula (1) that are of the more specific formula (2), wherein X^2 is NH.

10 Figures 2 and 3 show reaction schemes for syntheses of compounds of formula (2) wherein X^2 is O.

 Figure 4 shows the synthesis of compounds of formula (2) wherein S^x is $-O-C=O$ or $-NH-C=CO$.

Modes of Carrying Out the Invention

15 The compounds of formula (1) are prodrugs which can be used selectively to target tissues having GST complements which are elevated or which are peculiar in specificity to the prodrug provided. The specificity of the prodrug with respect to elevated classes of GST
20 isoenzymes can be determined by appropriate choices of YCO and AA_C. Thus, these prodrugs, in addition to being selective for cells with elevated GST complements per se, can be used in a finely tuned protocol to target cells which have elevated levels of a particular isoenzyme of
25 the GST group.

 In addition to selectivity, the prodrugs of the invention are able to resist efflux of the activated drug from the target cells, thus permitting lower dosages of the prodrug. Resistance to efflux may also be obtained
30 by selecting YCO and AA_C in the prodrugs disclosed in WO 95/09866 so that the liberated glutathione analog (i.e., YCO-NHCH(CH₂S^x-CH=CH₂)CO-AA_C) interacts with the MRP system to inhibit its ability to secrete additional substances when selectivity conditions permit such design
35 choices. However, resistance to efflux may also be obtained by supplying the prodrugs of the present invention of formula (1), wherein the activated drug or

other biologically active molecule remains tethered to the oxidized glutathione analog, typically a vinyl sulfone.

5 Method of Selecting Efflux Resistant Prodrugs

The prodrugs described in the above-incorporated WO 95/09866 can be used directly to provide biologically active agents to target tissues if the specificity required for the target permits the appropriate choices of YCO and AA_C so that the glutathione analog represented by the vinyl (typically) sulfone liberated when the biologically active agent is released interacts with the MRP clearance system so as to inhibit the ability of the system to effect clearance of the released biological moiety. Thus, for example, the glutathione analogs TER 106 (γ Glu-C(Bz)- β Ala); TER 222 (γ Glu-C(Bz)-Gly); and TER 117 (γ Glu-C(Bz)- ϕ Gly) have been assessed for their ability to interact with the MRP pump in assays described by Akerboom, et al. *Biochim Biophys Acta* (1992) 1103:115-119 and as described in Example 1 below. The results show that TER 222 and TER 106 interact with MRP so as to reduce the transport of radiolabeled GSH analog through the protein pump. However, TER 117 does not. A prodrug constructed from TER 117 as described in the above-referenced PCT application, TER 286, has the desired isoenzyme specificity for cells having GST complements high in the P1-1 isoform; however, this form of the prodrug would not advantageously inhibit efflux. On the other hand, prodrugs constructed from TER 222 and TER 106, provided the GST specificity is appropriate for the target tissue, could reasonably be used.


Thus, one aspect of the present invention is concerned with a method of enhancing the effectiveness of prodrug administration by first assessing the ability of glutathione analogs that can be incorporated in oxidized form into the classical prodrug constructs described in

the above-referenced PCT application to select an analog that interacts with MRP. Methods similar to those described in Example 1 could, for example, be used. The successful candidate, which does exhibit interaction, is then used to synthesize the appropriate prodrug, provided the specificity conferred on the prodrug by the analog is consistent with the determined GST complement of the target cell. The designed prodrug is then administered to a subject in need of the biologically active agent contained in the prodrug.


Tethered Prodrugs

It may be difficult to find a glutathione analog which has both the ability to interact with the MRP clearance system and to confer the appropriate specificity on the prodrug. A more universally applicable method of ensuring both the required specificity and the efflux inhibition is the use of the tethered prodrugs of formula (1). In these compounds, the glutathione analog portion can be chosen on the basis of its specificity-conferring properties, and the biologically active moiety, because it remains tethered to the prodrug, although activated by partial release, is itself resistant to transport by the MRP pump, since the GSH moiety in this configuration is a poor substrate for the MRP pump.

The compounds of the invention of formula (1) are comprised of a tripeptide which is a glutathione analog coupled to a tethered leaving group through a molecular system which permits release of one of the bonds of the leaving group when the compound of formula (1) is treated with the appropriate GST. The release occurs through a " β -elimination" -- i.e., the removal of the proton on the carbon α to the electron-poor carbon, sulfur or selenium releases electrons which are ultimately absorbed by an electronegative atom in the biomolecule. This can be shown schematically as follows:



As shown, the electrons contained in covalent bond (a) are released into the biomolecule. However, the biomolecule remains tethered to the remainder of the molecule either through C^* , C^+ , or a carbon contained in the conjugated system if present. Thus, compounds of formula (1') result:




30

Because of the release of electrons into the biomolecule and severing covalent bond (a), the biomolecule becomes biologically active. However, because the biomolecule remains tethered to the remainder of the glutathione analog as shown, it is resistant to clearance systems associated with the multidrug resistance associated protein.

35


A specific instance of this release is shown for one embodiment of the compounds of formula (2a) below:

40



The electron pair can be released to X^1 adjacent to the P atom directly through β -elimination as shown above or through a system of conjugation represented by $(\text{conj})_m$ in formula (1). Thus, theoretically any number of conjugated π bonds may be included in (conj) but the efficiency of the electron transport is believed to decline as this number increases.

After activation by the appropriate GST, the resulting molecule is an activated biologically active moiety wherein the biologically active portion is tethered to the glutathione analog as shown in formula (2a')



Because the partial release exposes the entity $P(O)X^1X^2-Z$, this moiety can now provide biological activity.


20 Suitable embodiments for Z include those which
generate drugs which may be cytotoxic to unwanted cells.


Such drugs include the phosphoramidate mustards. Preferred forms of the phosphorodiamidate mustards are
 $\text{-OP(O)(N(CH}_2\text{CH}_2\text{Cl})_2)_2$, $\text{-OP(O)(N(CH}_2\text{CH}_2\text{Br})_2)_2$,
 25 $\text{-OP(O)(NHCH}_2\text{CH}_2\text{Cl})_2$ and $\text{-OP(O)(NHCH}_2\text{CH}_2\text{Br})_2$; thus, in

these cases X^1 is identical to Z in formula (2a'). However, compounds wherein Z is, e.g., $N(CH_2CH_2Cl)_2$ and X^1 is O are also preferred.

Because the mustards remain tethered to the glutathione analog as shown above, they are unlikely to react with glutathione *per se* in the conventional manner, wherein a chloride ion is released from the 2-chloroethyl moiety to couple glutathione directly to the drug. Steric interference in the GST active site by the conjugated GSH will diminish the opportunity for a free GSH to be coupled to the phosphoramidate for efflux in the pump. Thus, absent this coupling, they cannot be transported out of the cell using the MRP clearance pathway.


15 Another embodiment of the compounds of the invention is illustrated by those of formula (3).






As explained above, the number of H associated with the carbamoyl N will depend on whether, in the drug, the N is part of a 1° or 2° amine.

Suitable embodiments of the "drug residue-NH" include nitrogen-containing antibiotics such as dynemycin-A and mitomicin-C. Thus, typical embodiments of the invention involving these pharmaceutically active compounds would include:



and



It will be seen that the compounds of formula (3) are characterized by including the amino group of a drug in a carbamoyl linkage to a glutathione analog. The covalent bond (a) of the carbamoyl is cleavable by
5 electron donation originating from abstraction of a proton adjacent to S^x , liberating CO_2 . A second covalent bond originating elsewhere in the drug and attached to C^+ , C^+ , or a carbon in the conjugated system, if present, tethers the (drug residue)-NH to the glutathione analog.
10 Depending on the nature of the drug, the points of attachments will be determined as would be understood by those of ordinary skill.

The structural requirements for the prodrugs of the invention are outlined above.

15 The R substituents play no direct part in the release of electrons to the biomolecule and simply must be noninterfering substituents. The rate of β -elimination can, however, be controlled by the nature of these R groups; by choosing electron withdrawing or
20 electron donating substituents the rate of elimination can be accelerated or decreased. Suitable substituents for R include H, substituted or unsubstituted alkyl (1-6C) substituted or unsubstituted aryl (6-12C), substituted or unsubstituted aryl alkyl (7-12C), cyano,
25 halo, substituted or unsubstituted alkoxy (1-6C), substituted or unsubstituted aryloxy (6-12C) or substituted or unsubstituted arylalkyloxy (7-12C).

Alkyl, aryl, and arylalkyl have their conventional meanings; alkyl groups are straight,
30 branched chain or cyclic saturated hydrocarbon moieties such as methyl, tert-butyl, cyclohexyl, and the like. Aryl groups include aromatic systems such as phenyl, naphthyl, pyridyl and the like. Arylalkyl substituents contain an aryl moiety coupled to the remainder of the
35 molecule through an alkylene moiety. Such groups include, most commonly benzyl, phenylethyl, 2-pyridylethyl, and the like.

Suitable substituents in the substituted forms include halo, SR", OR", and NR₂" wherein R" is H or lower alkyl (1-4C).

Preferred embodiments for each R independently are H, lower alkyl (1-4C) and phenyl, especially H or lower alkyl (1-4C). In particularly preferred embodiments, R is H and m=0. However, any noninterfering substituents may be used as R; these substituents are independently embodied.

10 The embodiments of YCO and -AA_C determine the nature of the glutathione-like tripeptide. A preferred embodiment is that wherein YCO is γ-glutamyl and AA_C is glycine, phenylglycine, β-alanine, alanine or phenylalanine, resulting in the tripeptide glutathione or
15 a close analog. However, alternative embodiments of YCO include β-Asp, Glu, Asp, γ-GluGly, β-AspGly, GluGly and AspGly. Alternative embodiments of AA_C include, along with the preferred glycine, phenylglycine, β-alanine, alanine, and unsubstituted phenylalanine: valine,
20 4-aminobutyric acid, aspartic, phenylglycine, histidine, tryptophan, tyrosine, and substituted phenylalanine. Suitable phenylalanine substituents are as described above for the substituted forms of R.

The compounds of the invention may also be
25 prepared in the forms of their esters or amides, mixed ester/amides or as the salts. The esters, amides or salts are formed with any or all carboxyl groups present in the molecule; hence, included in this group are monoesters, diesters, and, if applicable, triesters.
30 Similarly, monoamides, diamides, or, if applicable, triamides are included. Mixed ester/amides are also part of the invention.

The esters or amides may be alkyl (1-6C), alkenyl (1-6C) or arylalkyl (7-12C). Alkyl esters of the
35 free carboxyls are esters of the straight- and branched-chain alkyl alcohols (1-6C) such as methanol, ethanol,

isopropanol, t-butanol, n-hexanol and the like. Suitable alkyl (1-6C) amides are those of primary straight- or branched-chain alkyl amines, such as methylamine, ethylamine, n-propylamine, isopentylamine, and
5 isohexylamine. Alkenyl esters are similar, but contain at least one double bond. Arylalkyl is as defined above.

The alcohols or amines may also carry noninterfering substituents such as halo, alkoxy, or alkyl amines. The esters and amides are prepared using conventional
10 techniques, with suitable protection of any alcohol or amino functional groups in the compound of formula (1).


The salts of the compounds of the invention may be formed of inorganic or organic bases to form the basic salts of the free carboxyl groups or may be formed from
15 organic or inorganic acids to obtain the acid addition salts of free amino groups. Thus, the salts may be of inorganic bases such as sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonium hydroxide, magnesium hydroxide, and the like, or of organic bases
20 such as trimethylamine, pyridine, pyrimidine, piperidine, lysine, caffeine, and the like. The acid addition salts may be formed from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, and the like, or from organic acids such as acetic acid,
25 propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, and the like. Salts of citric acid are preferred.

The salts of the compounds of formula (1) are
30 formed in standard protocols by treating with the appropriate base or acid at a temperature of from about 0°C to about 100°C, preferably at room temperature either in water alone or in combination with an inert water-miscible organic solvent such as methanol, ethanol or
35 dioxane.


Preferred forms of the compounds of formula (1) are those wherein S^x is S=O, O=S=O, S=NH, HN=S=O, Se=O,

SUBSTITUTE SHEET (RULE 26)

O=Se=O, Se=NH, HN=Se=O, S⁺R' wherein R' is alkyl (1-6C), more preferably wherein S^x is O=S=O or S=O, particularly O=S=O. Also preferred are those compounds wherein m=0 and all R substituents are H. Particularly preferred
 5 embodiments of formula (1) are those represented by formulas (2) and (3). Particularly preferred among compounds of formula (2) are those wherein Z is N(CH₂CH₂Cl)₂ or NHCH₂CH₂Cl or the analogs containing Br in place of Cl. A particularly preferred embodiment of n is
 10 2. A particularly preferred embodiment of X¹ is O and of X² is O or NH or N(CH₂CH₂Cl)₂ or NHCH₂CH₂Cl or the analogs containing Br in place of Cl. Especially preferred are compounds of the following formulas:




25 and



wherein YCO is γGlu and AA_c is phenylglycine, glycine, or β-alanine, and Z is N(CH₂CH₂Cl)₂ or NHCH₂CH₂Cl.

However, the selection of YCO and AA_c can be widely varied within the definition set forth above to
 40 confer the appropriate specificity on the prodrug.

Preferred embodiments of the compounds of formula (3) are of the formula



wherein S^x is $O=S=O$, and in particular where the (drug residue)-N represents mitomycin-C or dynemycin-A.

Particularly preferred are the compounds of formulas (3a)

and (3b) set forth above wherein YCO is γ -Glu and AA_C is phenylglycine, glycine or β -alanine.

As above, the selection of YCO and AA_C can be varied to confer appropriate specificity on the prodrug.

25 Use of the Invention Compounds for Targeted Drug Delivery

In one aspect the invention provides a vehicle for delivering drugs to tissues specifically based on their GST content wherein efflux via MRP is diminished. The biologically active agent, when partially released in the target tissue will exert its desired effects selectively in that target tissue. The target cells where the partial release will occur can be regulated by manipulating the nature of the glutathione analog portion of the molecule.

As described above, the various tethered prodrugs of the invention are selective for the various isozymes of GST whose levels may be elevated in tumor cells. As with the prodrugs described in WO 95/09866, by determining the profile of GST isoenzyme levels in the tumor target, and matching this with the specificity of the prodrug, maximum effectiveness against the tumor cell will be obtained and maximum selectivity for the tumor

cell as opposed to normal tissue can be achieved. The selectivity of the prodrug depends to a significant extent on the choice of the glutathione analog used as a component of the drug.

5 In illustrative compounds described in the PCT application, TER 231 is especially susceptible to cleavage by GST M1a-1a; TER 303 is especially susceptible to cleavage by A1-1; TER 286 is particularly susceptible to cleavage by P1-1 and A1-1, while TER 296 is
10 selectively cleaved by P1-1. Thus, in treating a tumor having elevated levels of P1-1, use of a compound of formula (1) having the tripeptide contained in TER 296 or TER 286 would be preferred. The relevant isoenzyme, GST P1-1 is elevated in more than 75% of human tumor
15 specimens from breast, lung, liver and colon.

The appropriate choice of prodrug is also facilitated by determining the GST complement of the cells to be treated in comparison with normal tissues. Detailed instructions for obtaining such complements are
20 found in PCT application US 92/03537 published in October of 1992. The description in this PCT application sets forth methods for determining which GST isoenzymes are elevated in particular tissues.

The compounds of formula (1) are administered
25 as pharmaceutical compositions in usual formulations such as those outlined in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, latest edition. Typical formulations will include those for injection, for transdermal and transmucosal administration, and for
30 oral administration. The formulations, depending on the intended mode, may be liquids, syrups, powders, capsules, suppositories, and the like. The compounds of the invention may be included in liposomes, or in other emulsified forms. Protocols for administration and
35 suitable formulations are subject to optimization using standard procedures known to those in the art.

The antitumor activity of the invention compounds of formula (2) coupled with phosphorodiamidate mustard or other toxins can be assessed using a number of human tumor xenografts to determine tumor growth inhibition or a B16 mouse melanoma and measuring the
5 prolongation of survival to determine the efficacy of particular compounds.

The compounds of the invention in general will be administered with respect to the appropriate
10 indication for the biomolecule. Thus, for treatment of infections, embodiments wherein the biomolecule contains a moiety with antibiotic activity will be employed; for antitumor indications, chemotherapeutic agents will be included in the biomolecule; and the like. Suitable
15 indications will depend on the nature of the moiety contained within the biomolecule as is understood by the skilled practitioner. The clearance systems described operate, not only in mamalian systems, but in living systems in general. Thus, an appropriate biologically
20 active compound can be administered to any suitable recipient subject, including insects, parasites, or plants. The choice of biomolecule will depend on the nature of the intended effect and the nature of the subject.

25

Synthesis of the Invention Compounds

The compounds comprising glutathione or its analogs described above coupled to a desirable biologically active moiety can be synthesized using means
30 generally known in the art. Where S^x is an oxidized form of S or Se, the methods illustrated below can be used, incorporating modifications which render them applicable to desired compounds of the invention.

Thus, for example, compounds of formula (1)
35 wherein S^x is $S=O$, $Se=O$, $O=S=O$ or $O=Se=O$ can be produced from the corresponding compounds wherein S or Se is in reduced form by oxidation with mild oxidizing agents such

as peroxide or peracetate. Compounds of formula (1) wherein S^x is $S=NH$, $Se=NH$, $O=S=NH$, or $O=Se=NH$ can be obtained by treatment of the appropriate precursor having reduced S or Se, or a partially oxidized form, with chloramine T under conditions known in the art. Alternatively, the method of Whitehead, J.K. et al., *J Chem Soc* (1952) 1572-1574, may be used. Dipeptide precursors can be converted to the compound of formula (1) by coupling the YCO moiety or the AA_C amino acid to the appropriate dipeptide using standard peptide coupling techniques. When S or Se are in reduced form in the dipeptide, these compounds may, similarly, be converted to tripeptides with S or Se reduced. Compounds of formula (1) wherein S^x is a sulfonium ion, i.e., is S^+ ; may be synthesized by treating compounds with reduced S with alkyl halides under suitable conditions to alkylate the sulfide, or intermediates can be synthesized from corresponding dipeptide compounds. R' is alkyl (1-6C) as defined above. Preferred alkyl halides for reaction to form, ultimately, compounds of formula (1) in this embodiment are the iodides.

For compounds of formula (1) wherein S^x is $O-C=O$ are obtained using as a dipeptide or tripeptide starting material analogs of glutathione wherein serine substitutes for the cysteine moiety. Compounds are then obtained by esterification of the di- or tripeptide containing serine. Where S^x is $NH-C=O$, the corresponding amidation reaction is effected with analogs wherein 2,3-diaminopropionic acid replaces cysteine.

Shown in Figure 1 is a sequence of reactions to obtain the precursor to the embodiment wherein S^x is $O=S=O$ for compounds of formula (2) where X^2 is NH . The sulfone is obtained from the sulfur in reduced form by treating with mild oxidizing agents as described above, such as peracetic acid.

The last step in the reaction sequence prior to oxidation to the sulfone is coupling of the glutathione

analog to a brominated form of the tethered moiety. The construction of the tethered moiety is as follows: The starting material, 4-aminobutyric acid, is first acetylated in acetic anhydride and base such as pyridine or triethylamine to give Compound A. The bromine α to the carboxyl is introduced using Hell-Volhard-Zelinski conditions and the resulting compound is hydrolyzed in base to obtain Compound C, γ -amino- α -hydroxybutyric acid.

Compound C is reduced with lithium aluminum hydride to obtain the diol D, which is treated with dihydropyran in the presence of an acid catalyst to provide the tetrahydropyranyl alcohol amine, E. Compound E is then treated with phosphorous oxychloride and base to obtain Compound F, which is purified by crystallization or chromatography. The isolated Compound F is then treated with bis-2-chloroethylamine and base, followed by reaction with HBr to give Compound G, which is isolated and reacted with a suitable glutathione analog to give the sulfide, H, under reductive alkylation conditions (NaBH₄, ammonia, inert atmosphere). Oxidation of compound H to the desired compound of formula (2) with peracetic acid is followed by purifying the product with HPLC.

Figures 2 and 3 show the synthesis of alternative forms of the compounds of formula (2) wherein X² is O. In Figure 2, glycerol (A2) is reacted with acetone under mildly acidic dehydrating conditions typified by Dean-Stark to give the corresponding ketal, the six-membered ring B2. Displacement of the ring hydroxyl with chloride using SOCl₂ in pyridine provides the resultant C2 which is then hydrolyzed under mildly acidic conditions to obtain 1,3-dihydroxy-2-chloropropane, D2. D2 is treated with phosphorus oxychloride to obtain the cyclic diester E2 which is then reacted with bis-(2-chloroethyl)amine in the presence of base, preferably triethylamine, to give F2. F2 is then reacted with the desired glutathione analog, such as GSH

itself, under reducing conditions (NH_4OH , NaBH_4 , argon) to provide the intermediate sulfide which is purified and oxidized to provide the compound of formula (G2). In G2 as shown, S^x is $\text{O}=\text{S}=\text{O}$, X^1 and X^2 are both O, and Z is
5 $\text{N}(\text{CH}_2\text{CH}_2\text{Cl})_2$. In formula (G2), n is 1 and m is 0.

Also shown in Figure 2 is the resultant G2' when the hydrogen α to the sulfone is abstracted and the prodrug is converted to the tethered active form.

Figure 3 shows the synthesis of the analogous
10 compound of formula (2), J3, wherein $m=1$. Release of the hydrogen ion α to the sulfone in J3 provides the tethered active form shown as J3'.

To synthesize J3, the ketal prepared in Figure 2 is oxidized under anhydrous conditions using pyridinium
15 chlorochromate (PCC) to obtain the corresponding ketone B3. B3 is then treated with vidiic reagent C3 to obtain the silylated conjugated compound D3. D3 is desilylated with tetrabutylammonium fluoride (TBAF) to obtain the allyl alcohol D2, which is then chlorinated with SOCl_2 in
20 pyridine to obtain F3. The remaining steps are similar to those shown in Figure 2. The ketal is hydrolyzed to give the diol G3 which is then treated with phosphorus oxychloride in the presence of base resulting in phosphorylation to obtain H3. H3 is then treated with
25 bis-(2-chloroethyl)amine and base to give I3 which is then purified and then coupled to the desired glutathione analog under basic reducing conditions, as were set forth in Figure 2 to provide the sulfide, which is then
purified and oxidized to obtain J3, the final product.

30 Figure 4 shows the synthesis of compounds of formula (2) wherein S^x is $-\text{O}-\text{C}=\text{O}$ or $-\text{NH}-\text{C}=\text{O}$. As shown in Figure 4, the triol A4 is reacted with acetone to provide the ketal analogous to the formation of B2 as shown in Figure 2. B4 is then oxidized in two stages, first to an
35 aldehyde under mild conditions using pyridinium chlorochromate (PCC) and then in air to provide the corresponding carboxylic acid C4 which is then hydrolyzed

to the diol. Analogous to the sequence of reactions in Figures 2 and 3, the diol is treated with phosphorus oxychloride in base to obtain the phosphorylated product which is then derivatized with bis-(2-chloroethyl)amine in the presence of base to obtain F4. F4 is reacted with the desired glutathione analog in which the position of the sulfhydryl is replaced with OH or NH₂ to obtain the resulting ester or amide linked prodrug shown as H4. This coupling is effected using standard reagents such as dicyclohexylcarbodiimide or N-hydroxysuccinimide. During this step, the glutamic acid amine is protected using standard amino protecting groups. Abstraction of the hydrogen α to the carbonyl group results in the tethered active form.

15

The following examples are intended to illustrate but not to limit the invention.

Example 1

20

Determination of the Interaction of Glutathione Analogs with MRP

Two indirect measures of interaction of test compounds in the MRP system of human erythrocytes were used. The first was stimulation of basal Mg⁺² stimulated ATPase activity, the other was inhibition of transport of tritiated dinitrophenyl-S-glutathione.

In the first method, the method of Bartosz, M. et al, *Biochem Mol Biol Int* (1994) 34:521-529 was used. Briefly, the compounds were added to erythrocyte membranes in a medium containing 100 mM Tris HCl, pH 4, 10 mM MgCl₂, 1 mM ATP, 0.1 mM ouabain and 1 mM EGTA with an incubation at 37°C for 30 minutes. Stimulation of ATPase activity was measured as described.

In this assay, TER 117 did not stimulate ATPase activity. TER 222 stimulated this activity, resulting in a V_{max} of 125.9 mM/mg protein per hr; V_{max} observed for TER 106 was 209.6 mM/mg protein per hr; K_m for TER 222

was 0.385 mM; for TER 106, 1.82 mM. The foregoing values were averages of three separate determinations.

In the alternative method, the uptake of tritiated DNP-glutathione conjugate by inside-out vesicles of human erythrocytes was determined as described in Akerboom, T.P.M. et al, *Biochim Biophys Acta* (1992) 1103.:115-119. The labeled DNP-GSH concentration was 5 μ M and the compounds were added at a final concentration of 1 μ M; uptake of labeled DNP-GSH was measured after 15 minutes incubation at 37°C. As a mean of three separate trials, TER 222 showed 62.5% inhibition of labeled conjugate uptake; TER 106 showed a 66.2% inhibition; and TER 117, 0.2% inhibition.

Thus, prodrugs containing TER 222 and TER 106 as the glutathione analog, provided the specificity for the GST complement of the target tissue is appropriate, can usefully be supplied, possibly without the necessity of tethering the biologically active agent.

20

Example 2

Selective Activation of Phosphoroamidates


by GST Isoenzymes

The selectivity of activation of the compounds of the invention is analogous to that described by Lyttle, M.H. et al, *J Med Chem* (1994) 37:1501-1507. Briefly, depending on the analog of glutathione used in the conjugate, selectivity is shown for GSTs of the isoforms A1-1, M1a-1a and P1-1. Determination of *in vitro* cytotoxicity of the compounds of the invention is conducted as described in this publication.

30

Claims

1. A compound of the formula:



and the amides, esters, mixed ester/amides and salts thereof, wherein:

S^x is $S=O$, $O=S=O$, $S=NH$, $HN=S=O$, $Se=O$, $O=Se=O$, $Se=NH$, $HN=Se=O$, S^+R' wherein R' is alkyl (1-6C), or S^x is $-O-C=O$ or $-HN-C=O$;

YCO is selected from the group consisting of γ -Gly, β -Asp, Glu, Asp, γ -GluGly, β -AspGly, GluGly and AspGly;

AA_C is an amino acid linked through a peptide
30 bond to the remainder of said compound of formula (1);

each R is independently H or a noninterfering substituent;

35 (conj) is a conjugated system;

```
m is 0 or 1;
```

and wherein each of the dotted lines represents
40 a covalent bond between the biomolecule and C⁺, C⁺, or a


carbon in the conjugated system if present with the proviso that one and only one said bond is present; and

wherein "biomolecule" represents a moiety which
5 becomes biologically active when covalent bond (a) is
cleaved to donate an electron pair to biomolecule. .

2. The compound of claim 1 wherein S^x is $S=O$, $O=S=O$, $S=NH$, $HN=S=O$, $Se=O$, $O=Se=O$, $Se=NH$, $HN=Se=O$, or S^+R' wherein R' is alkyl (1-6C).

3. The compound of claim 2 wherein S^x is $O=S=O$.

15 4. The compound of claim 1 which is of the
 formula:



20 and the amides, esters, mixed ester/amides and salts thereof, wherein:

S^x is S=O, O=S=O, S=NH, HN=S=O, Se=O, O=Se=O, Se=NH, HN=Se=O, S^+R' wherein R' is alkyl (1-6C), or S^x is -O-C=O or -HN-C=O;

YCO is selected from the group consisting of γ -Gly, β -Asp, Glu, Asp, γ -GluGly, β -AspGly, GluGly and AspGly;

AA_C is an amino acid linked through a peptide bond to the remainder of said compound of formula (1);

each R is independently H or a noninterfering substituent;

(conj) is a conjugated system;

m is 0 or 1;

n is an integer of 0-4;

each of X¹ and X² is independently S, O, or NR' wherein R' is H or a noninterfering substituent; and

Z is a moiety which, when associated with P(O)X¹X², results in a biologically active moiety;

and wherein each of the dotted lines represents a covalent bond between (CR₂)_n or X² and C*, C⁺, or a carbon in the conjugated system if present with the proviso that one and only one said bond is present.

5. The compound of claim 4 wherein said biologically active moiety is a tethered phosphoramidate mustard or a tethered phosphorodiamidate mustard.

6. The compound of claim 5 wherein m=0; and/or

wherein YCO is γ-glutamic acid; and/or

wherein AA_C is alanine, phenylalanine, glycine or phenylglycine; and/or

wherein each R is independently H, lower alkyl (1-4C) or phenyl; and/or

wherein Z is $N(CH_2CH_3)_2$, $N(CH_2CH_2Cl)_2$, $NHCH_2CH_2Cl$, $N(CH_2CH_2Br)_2$, or $NHCH_2CH_2Br$; and/or


5 wherein S^x is $O=S=O$.

7. The compound of claim 6 wherein each R is H.

10


8. The compound of claim 6 wherein AA_c is phenylglycine.

9. The compound of claim 6 which has the
15 formula



25

or




40 wherein YCO is γ Glu and AA_c is phenylglycine, glycine, or β -alanine, and Z is $N(CH_2CH_2Cl)_2$ or $NHCH_2CH_2Cl$.


10. A compound for the preparation of the
compound of claim 4 of the formula selected from the
45 group consisting of:

SUBSTITUTE SHEET (RULE 26)


(a)



(b)



and (c)



and the amides, esters, mixed ester/amides or salts thereof, wherein:

S^* is S^+ or S^x ;

S^+ is S or Se;

S^x is $\text{S}=\text{O}$, $\text{O}=\text{S}=\text{O}$, $\text{S}=\text{NH}$, $\text{HN}=\text{S}=\text{O}$, $\text{Se}=\text{O}$, $\text{O}=\text{Se}=\text{O}$, $\text{Se}=\text{NH}$, $\text{HN}=\text{Se}=\text{O}$, $\text{S}^+\text{R}'$ wherein R' is alkyl (1-6C), or S^x is $-\text{O}-\text{C}=\text{O}$ or $-\text{HN}-\text{C}=\text{O}$;

Y is selected from the group consisting of γ -Glu, β -Asp, Glu, Asp, γ -GluGly, β -AspGly, GluGly and AspGly;

- 31 -

AA_C is an amino acid linked through a peptide bond to the remainder of said compound of formula (1);

each R is independently H or a noninterfering substituent;

m is 0 or 1;

n is an integer of 0-4;


10

each of X¹ and X² is independently S, O, or NR' wherein R' is H or a noninterfering substituent; and

Z is a moiety which, when associated with P(O)X¹X², results in a biologically active moiety.

15

11. A method for producing the compound of the formula:



20

wherein YCO, AA_C, (conj), m, n, Z and R are as defined in claim 1, which method is selected from the group consisting of

25

a method comprising treating the compound a) of claim 10 with an oxidizing agent, when S^x is S=O, O=S=O, Se=O or O=Se=O;


30

a method comprising treating the compound a) of claim 10 with chloramine T, when S^x is S=NH or Se=NH;

SUBSTITUTE SHEET (RULE 26)

a method comprising treating the compound a) of claim 10 with an oxidizing agent and chloramine T, when S^x is $O=S=NH$ or $O=Se=NH$;


5 a method comprising treating the compound of the formula



10

with a compound that donates a moiety of the formula

15




20

when S^x is $O-C=O$;

25


a method comprising treating the compound of the formula



30

with a compound which donates a moiety of the formula

35



40

45


when S^x is $HN-C=O$;

a method comprising treating the compound a) of claim 10 with the halide of R', when S^x is S⁺R' wherein R' is alkyl (1-6C);

5 a method comprising coupling a residue of AA_C
to the compound of formula b) of claim 10; and

a method comprising coupling a residue of YCOOH to the compound of formula c) of claim 10.

12. The compound of claim 1 which has the formula



and the amides, esters, mixed ester/amides and salts thereof, wherein:

30

S^X is $S=O$, $O=S=O$, $S=NH$, $HN=S=O$, $Se=O$, $O=Se=O$, $Se=NH$, $HN=Se=O$, S^+R' wherein R' is alkyl (1-6C), or S^X is $-O-C=O$ or $-HN-C=O$;

35 YCO is selected from the group consisting of
 γ -Gly, β -Asp, Glu, Asp, γ -GluGly, β -AspGly, GluGly and
 AspGly;

AA_C is an amino acid linked through a peptide
40 bond to the remainder of said compound of formula (1);

each R is independently H or a noninterfering substituent;

(conj) is a conjugated system;

5

m is 0 or 1;

and wherein each of the dotted lines represents a covalent bond between the drug residue and C⁺, C⁺, or a carbon in the conjugated system if present with the proviso that one and only one said bond is present; and

wherein "drug residue" represents a moiety which becomes biologically active when covalent bond (a) is cleaved to donate an electron pair to N(H) of (drug residue)-N(H)- as shown in formula (3).

15

13. The compound of claim 12 wherein the (drug residue)NH(H) is an antibiotic or an antitumor agent.

20

14. The compound of claim 13 wherein the antibiotic is mitomycin-C.

15. The compound of claim 12 wherein m=0; and/or

25

wherein YCO is γ -glutamic acid; and/or

wherein AA_C is alanine, phenylalanine, glycine or phenylglycine; and/or

30

wherein each R is independently H, lower alkyl (1-4C) or phenyl; and/or

35

wherein (drug residue)NH is mitomycin-C or dynemycin-A; and/or



wherein S^x is $O=S=O$.

16. The compound of claim 15 wherein each R is H.

5

17. The compound of claim 15 wherein AA_C is phenylglycine.

18. The compound of claim 15 which has the
10 formula



15

wherein YCO is γ -Glu and AA_C is phenylglycine, glycine or β -alanine.

19. A pharmaceutical composition effective in
20 selectively treating target cells, which composition
comprises at least one compound of claim 1 in admixture
with a pharmaceutically acceptable excipient, said cells

having a complement of GST isoenzymes in which at least one GST isoenzyme is elevated, wherein said compound has been selected as susceptible to cleavage by said GST isoenzyme which is elevated in the GST complement of said
5 target cells.

20. A method to enhance the effectiveness of prodrug administration, which method comprises assessing a panel of candidate glutathione analogs for their
10 ability to interact with the MRP system;
selecting from said panel an analog which interacts with said MRP system;
synthesizing a prodrug which is a conjugate of said selected analog with a substance of the desired
15 biological activity; and
administering the resulting prodrug to a subject in need of treatment with the biologically active compound.




FIG. 1




FIG. 2




FIG. 3



INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/20042

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K5/037 C07K5/093 C07K5/113 C07K5/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 09866 A (TERRAPIN TECHNOLOGIES, INC., SAN FRANCISCO, US) 13 April 1995 cited in the application	1-8, 19, 20
Y	whole document	9-20
X	J.MED.CHEM., vol. 37, 1994, page 1501-1507 XP000652018 LYTTLE M.H. ET AL.: "Glutathione-D-transferase activates novel Alkylating Agents"	1-8, 19, 20
Y	whole document, esp. Fig. 1 and 8	9-20

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

14 April 1997

Date of mailing of the international search report

20.05.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Kronester-Frei, A

INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/US 96/20042

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BIOCHEM.BIOPHYS.ACTA, vol. 1103, no. 1, 1992, pages 115-119, XP000652753 AKERBOOM TH.P.M. ET AL.: "Low- and high-Km transport of dienitrophenyl glutathione in inside of vesicles from human erythrocytes" cited in the application whole document including Materials and Methods ---	9-20
A	WO 95 08563 A (TERRAPIN TECHNOLOGIES, INC., SAN FRANCISCO, US) 30 March 1995 whole document, especially Tables 5 and 6 and Pharmacological Implications on page 56ff, example 11 ---	1-20
P,X	J.MED.CHEM., vol. 39, 1996, pages 1796-1747, XP000652016 SATIAM A. ET L.: "Design, Synthesis and Evaluation of Latent Alkylating Agents Activated by Glutathion S-Transferase" whole document, esp. Fig.2 ---	1-20
P,X	WO 96 40739 A (TERRAPIN TECHNOLOGIES, INC., SAN FRANCISCO, US) 19 December 1996 Claims, page 9 -----	1-20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/20042

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-8, 19, 20
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/20042

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9509866 A	13-04-95	US 5545621 A	13-08-96
		US 5556942 A	17-09-96
		AU 676618 B	13-03-97
		AU 7962394 A	01-05-95
		AU 8072094 A	01-05-95
		CA 2173130 A	13-04-95
		EP 0721465 A	17-07-96
		WO 9509865 A	13-04-95
WO 9508563 A	30-03-95	US 5599903 A	04-02-97
		AU 7842194 A	10-04-95
		CA 2171453 A	30-03-95
		EP 0720620 A	10-07-96
		US 5556942 A	17-09-96
WO 9640739 A	19-12-96	AU 6108896 A	30-12-96